Skip to main content

Advertisement

Fig. 7 | Alzheimer's Research & Therapy

Fig. 7

From: SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

Fig. 7

SAR228810, the humanized version of SAR255952, has consistent activity in immunotolerized APPSL mice. Animals were depleted in immunocompetent cells by treatment with a monoclonal anti-CD4+ antibody before undergoing a weekly treatment with 10 mg/kg i.p. of the indicated amyloid β (Aβ) antibodies (labeled + in the micrographs). a Representative whole-scanned Aβ-immunostained sagittal brain tissue section illustrating the decrease in the extracellular Aβ peptide deposition process in cortical, hippocampal, and thalamic brain areas in representative immunotolerized mice chronically treated either with SAR255952 or SAR228810, in respect to immunotolerized or not Ctrl-igG1-treated mice. b Mean values of the total surface occupied by Aβ immunostaining measured in the cortex over eight sections per animal. The immunodepletion has no significant effect on the cortical Aβ peptide deposition process in Ctrl-IgG1-treated mice. c Mean ± SEM real-time PCR amplification readings for the brain inflammation marker cystatin F expression in the hippocampus. Statistical analysis denotes similar significant effects of both SAR228810 and SAR255952. Of note, there was no major effect of the immunotolerization on Aβ peptide deposition in the brain of APPSL mice. **p < 0.01, ***p < 0.001, versus Ctrl-IgG1-treated controls. Horizontal black lines and error bars denote mean ± SEM data

Back to article page